Q4 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at HC Wainwright raised their Q4 2025 EPS estimates for shares of Genmab A/S in a research note issued on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.51 for the quarter, up from their prior estimate of $0.40. HC Wainwright has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS and FY2026 earnings at $1.68 EPS.

Several other analysts also recently commented on GMAB. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Finally, Truist Financial reissued a “buy” rating and issued a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $39.25.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $32.63 on Friday. The stock has a 50-day simple moving average of $32.47 and a 200 day simple moving average of $29.11. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43. The stock has a market capitalization of $20.96 billion, a PE ratio of 13.89, a P/E/G ratio of 19.53 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in Genmab A/S by 17.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after purchasing an additional 135,814 shares during the last quarter. Squarepoint Ops LLC lifted its position in shares of Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares during the last quarter. Eagle Global Advisors LLC boosted its stake in shares of Genmab A/S by 16.3% during the 3rd quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock worth $7,498,000 after acquiring an additional 34,175 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Genmab A/S during the 2nd quarter worth approximately $257,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after acquiring an additional 2,084,966 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.